- Oops!Something went wrong.Please try again later.
SAN DIEGO, CA / ACCESSWIRE / December 22, 2021 / Shareholder rights law firm Robbins LLP is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to determine whether certain Spectrum officers and directors violated the Securities Exchange Act of 1934 and breached fiduciary duties to shareholders. Spectrum is a biopharmaceutical company that develops and commercializes oncology and hematology drug products. One product the Company has under development is ROLONTIS (eflapegrastim), a novel long-lasting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia.
If you would like more information about Spectrum Pharmaceuticals, Inc.'s misconduct, click here.
Spectrum Pharmaceuticals, Inc. (SPPI) May Have Materially Misrepresented the Likelihood ROLONTIS Would be Approved by the FDA
According to a class action complaint filed on behalf of Spectrum shareholders, Spectrum submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for ROLONTIS as a treatment chemotherapy-induced neutropenia (the "ROLONTIS BLA") in December 2018. In March 2019, Spectrum voluntarily withdrew its ROLONTIS BLA, and then resubmitted an updated ROLONTIS BLA in October 2019. During the relevant period, defendants touted the viability of ROLONTIS and the preparations the Company had made in advance of the FDA's inspection of its manufacturing facility. However, defendants made materially false and misleading statements and/or failed to disclose that the ROLONTIS manufacturing facility maintained deficient controls and/or procedures and that the deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form. As a result, Spectrum had materially overstated the ROLONTIS BLA's approval prospects.
On August 6, 2021, Spectrum announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of the Company's manufacturing facility would be necessary. On this news, Spectrum's stock price fell $0.70 per share, or over 21%, to close at $2.55 per share on August 6, 2021.
Spectrum Pharmaceuticals, Inc. (SPPI) shareholders have legal options. If you own shares of Spectrum Pharmaceuticals, Inc., contact us for more information about your rights.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Spectrum Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE: Robbins LLP
View source version on accesswire.com: